Confronto
AOD-9604 vs. MGF (Mechano Growth Factor)
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
221231-10-3
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Peso molecolare
1815.09 g/mol
2867.2 g/mol
Emivita
0.4 h
0.1 h
Sequenza
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYQPPSTNKNTKSQRRKGSTFEERKMeccanismo d'azione
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Modello animale
Studi
3
4
di cui sull'uomo
2
0
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between AOD-9604 and MGF (Mechano Growth Factor)?
- AOD-9604 is classified as "Crescita", while MGF (Mechano Growth Factor) is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. MGF (Mechano Growth Factor): Synthetic peptide corresponding to the C-terminal E-domain of the IGF-1 splice variant IGF-1Ec. Described in preclinical studies as a 'mechano-induced' skeletal muscle repair factor. No marketing approval; clinical use largely confined to the black market. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or MGF (Mechano Growth Factor)?
- The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "Modello animale" for MGF (Mechano Growth Factor). A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and MGF (Mechano Growth Factor) in Germany and the United States?
- Germania: AOD-9604 — Non approvato, MGF (Mechano Growth Factor) — Non approvato. Stati Uniti: AOD-9604 — Non approvato, MGF (Mechano Growth Factor) — Non approvato. These are factual summaries with source and review date on the individual pages.